Erratum: Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence (Angiogenesis (DOI 10.1007/s10456-013-9344-y));Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence

Angiogenesis

Volumn 16, Issue 3, 2013, Pages 663-674

  Zhang, Yin ^a   Hong, Hao ^b   Nayak, Tapas R ^b   Valdovinos, Hector F ^a   Myklejord, Duane V ^b   Theuer, Charles P ^c   Barnhart, Todd E ^a   Cai, Weibo ^a,b,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c TRACON Pharmaceuticals Inc   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Breast cancer; CD105 endoglin; Image guided surgery; ImmunoPET; Lung metastasis; Near infrared fluorescence (NIRF); Positron emission tomography (PET); Tumor angiogenesis

Indexed keywords

COPPER 64; ENDOGLIN; FIREFLY LUCIFERASE; FLUORESCENT DYE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TRC105; NOTA CETUXIMAB 800CW CU 64; NOTA TRC105 800CW CU 64; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BIOLUMINESCENCE; BREAST CANCER; CONTROLLED STUDY; DRUG HALF LIFE; DRUG STABILITY; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE; NEAR INFRARED FLUORESCENCE; NON INVASIVE MEASUREMENT; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR VOLUME;

MURINAE; MUS;

EID: 84879236498     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-013-9351-z     Document Type: Erratum

References (35)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
2. Eckhardt BL, Francis PA, Parker BS, Anderson RL (2012) Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 11:479-497
3. Weigelt B, Peterse JL, van 't Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591-602
4. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42:1S-93S
5. 18F-based radiotracers. Am J Nucl Med Mol Imaging 2:55-76
6. 18F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. Am J Nucl Med Mol Imaging 1:63-64
7. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
8. von Elstermann M (2008) Metastasis: which way to the lungs? Nat Rev Cancer 8:410-411
9. Ikushima H, Miyazono K (2010) TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10:415-424
10. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M (2010) Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 86:12-19
11. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, et al. (2008) Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14:1931-1937
12. 18F-FDG PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging 1:47-53
13. 11C-acetate. Am J Nucl Med Mol Imaging 2:33-47
14. James ML, Gambhir SS (2012) A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 92:897-965
15. Nolting DD, Nickels ML, Guo N, Pham W (2012) Molecular imaging probe development: a chemistry perspective. Am J Nucl Med Mol Imaging 2:273-306
16. Zhang Y, Hong H, Engle JW, Yang Y, Theuer CP, Barnhart TE, et al. (2012) Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody. Mol Pharm 9:645-653
17. 89Zr and IRDye 800CW. Mol Pharm 9:2339-2349
18. 89Zr and IRDye 800CW. Am J Transl Res 4:333-346
19. Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, et al. (2011) Endoglin-targeted cancer therapy. Curr Drug Deliv 8:135-143
20. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, et al. (2012) A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res 18:4820-4829
21. Cao Q, Cai W, Niu G, He L, Chen X (2008) Multimodality imaging of IL-18-binding protein-Fc therapy of experimental lung metastasis. Clin Cancer Res 14:6137-6145
22. 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging 39:138-148
23. Zhang Y, Hong H, Engle JW, Yang Y, Barnhart TE, Cai W (2012) Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging 2:1-13
24. Hong H, Benink HA, Zhang Y, Yang Y, Uyeda HT, Engle JW, et al. (2011) HaloTag: a novel reporter gene for positron emission tomography. Am J Transl Res 3:392-403
25. 3. Cancer Res 66:9673-9681
26. 66Ga-labeled nano-graphene. Biomaterials 33:4147-4156
27. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, et al. (2011) Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging 38:1335-1343
28. Wadas TJ, Wong EH, Weisman GR, Anderson CJ (2010) Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 110:2858-2902
29. 64Cu-labeled antibody. Nucl Med Biol 38:29-38
30. Geus-Oei LF, Oyen WJ (2008) Predictive and prognostic value of FDG-PET. Cancer Imaging 8:70-80
31. 18F FDG PET/CT in the management of breast cancer. Ann Nucl Med 21:33-38
32. van Dongen GA, Vosjan MJ (2010) Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm 25:375-385
33. Wu AM (2009) Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med 50:2-5
34. 61/64Cu- labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging (ePub)
35. 2 antibody fragment. Mol Pharm (ePub)